v3.26.1
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Total
Redeemable Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at Dec. 31, 2024 $ (96,616)     $ 19,945   $ (116,561)
Balance, Shares at Dec. 31, 2024     1,356,431      
Temporary Equity Balance at Dec. 31, 2024   $ 45,999        
Temporary Equity Balance, Shares at Dec. 31, 2024   43,151,340        
Premium on issuance of convertible promissory notes 186     186    
Issuance of Series B-2 redeemable convertible preferred stock upon conversion of convertible promissory notes in connection with the Merger   $ 3,695        
Issuance of Series B-2 redeemable convertible preferred stock upon conversion of convertible promissory notes in connection with the Merger, Shares   794,499        
Conversion of convertible promissory notes into common stock in connection with the Merger 20,799     20,799    
Conversion of convertible promissory notes into common stock in connection with the Merger, Shares     3,418,839      
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger   $ (49,694)        
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger, Shares   (43,945,839)        
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger 49,694   $ 1 49,693    
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger, Shares     8,859,474      
Recognition of AlloVir common stock outstanding at the closing of the Merger 104,990   $ 1 104,989    
Recognition of AlloVir common stock outstanding at the closing of the Merger, Shares     5,067,674      
Transaction costs related to the Merger $ (5,357)     (5,357)    
Proceeds from exercise of stock options, Shares 0          
Stock-based compensation expense $ 374     374    
Unrealized loss on marketable securities, net of tax 0          
Net loss (10,196)         (10,196)
Balance at Mar. 31, 2025 63,874   $ 2 190,629   (126,757)
Balance, Shares at Mar. 31, 2025     18,702,418      
Balance at Dec. 31, 2025 78,814   $ 2 238,805 $ 6 (159,999)
Balance, Shares at Dec. 31, 2025     22,902,418      
Proceeds from exercise of stock options $ 74     74    
Proceeds from exercise of stock options, Shares 89,873   89,873      
Stock-based compensation expense $ 580     580    
Unrealized loss on marketable securities, net of tax (55)       (55)  
Net loss (10,856)         (10,856)
Balance at Mar. 31, 2026 $ 68,557   $ 2 $ 239,459 $ (49) $ (170,855)
Balance, Shares at Mar. 31, 2026     22,992,291